caa a22 4500 445314966 CHVBK 20180317142643.0 cr unu---uuuuu 170323e20110701xx s 000 0 eng 10.1007/s10552-011-9769-9 doi (NATIONALLICENCE)springer-10.1007/s10552-011-9769-9 Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype [Elektronische Daten] [Theodore Brasky, Matthew Bonner, Kirsten Moysich, Christine Ambrosone, Jing Nie, Meng Tao, Stephen Edge, Bhaskar Kallakury, Catalin Marian, David Goerlitz, Maurizio Trevisan, Peter Shields, Jo Freudenheim] Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk of breast cancer, though findings have been inconsistent. This inconsistency may result from differences in etiology for breast tumors of different subtypes. We examined the association between NSAID use and breast cancer characterized by molecular subtypes in a population-based case-control study in Western New York. Cases (n=1,170) were women with incident, primary, histologically confirmed breast cancer. Controls (n=2,115) were randomly selected from NY Department of Motor Vehicles records (<65years) or Medicare rolls (≥65years). Participants answered questions regarding their use of aspirin and ibuprofen in the year prior to interview and their use of aspirin throughout their adult life. Logistic regression models estimated odds ratios (OR) and 95% confidence intervals (95% CI). Recent and lifetime aspirin use was associated with reduced risk, with no differences by subtype. Recent use of ibuprofen was significantly associated with increased risk of ER+/PR+(OR 1.33, 95% CI: 1.09-1.62), HER2− (OR 1.27, 95% CI: 1.05-1.53), and p53− breast cancers (OR 1.28, 95% CI: 1.04-1.57), as well as luminal A or B breast cancers. These findings support the hypothesis of heterogeneous etiologies of breast cancer subtypes and that aspirin and ibuprofen vary in their effects. Springer Science+Business Media B.V., 2011 Aspirin nationallicence Breast cancer nationallicence HER-2 nationallicence Hormone receptor nationallicence Ibuprofen nationallicence P53 nationallicence Non-steroidal anti-inflammatory drugs nationallicence Brasky Theodore Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut Bonner Matthew Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut Moysich Kirsten Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut Ambrosone Christine Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut Nie Jing Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut Tao Meng Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut Edge Stephen Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA aut Kallakury Bhaskar Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut Marian Catalin Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut Goerlitz David Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut Trevisan Maurizio Nevada System of Higher Education, Las Vegas, NV, USA aut Shields Peter Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut Freudenheim Jo Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut Cancer Causes & Control Springer Netherlands 22/7(2011-07-01), 965-975 0957-5243 22:7<965 2011 22 10552 https://doi.org/10.1007/s10552-011-9769-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-011-9769-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Brasky Theodore Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Bonner Matthew Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Moysich Kirsten Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Ambrosone Christine Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Nie Jing Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Tao Meng Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Edge Stephen Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Kallakury Bhaskar Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut NATIONALLICENCE 700 1- Marian Catalin Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut NATIONALLICENCE 700 1- Goerlitz David Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut NATIONALLICENCE 700 1- Trevisan Maurizio Nevada System of Higher Education, Las Vegas, NV, USA aut NATIONALLICENCE 700 1- Shields Peter Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA aut NATIONALLICENCE 700 1- Freudenheim Jo Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/7(2011-07-01), 965-975 0957-5243 22:7<965 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 445314966 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer